Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
UBS analyst Joshua Spector cut target prices on two chemicals names on Tuesday. Albemarle dropped to $150 from $175, keeping a Buy rating. Air Products and Chemicals fell to $305 from $336, with a Hold maintained.
Albemarle carries short interest of 9.6% of free float, reflecting persistent bearishness on lithium prices. UBS's cut signals the recovery trade may take longer than bulls expected.
Citi's Joanne Wuensch ran in the opposite direction on Johnson & Johnson. She lifted the target to $303 from $298, reiterating Buy, as Medicare Advantage penetration hits 51.1% in June, the highest reading on record since 2013 according to ORTEX Alt Data. That tailwind supports medtech and pharma broadly.
Wuensch cut targets on three other medtech names. GE HealthCare fell to $71 from $75. slipped to $48 from $50. was trimmed to $27 from $28. All three remain Hold-rated.
Also at Citi, Benjamin Gerlinger raised targets on two custody bank names. State Street went to $212 with a Buy. Northern Trust moved to $186, staying at Hold.
PTC Inc. saw multiple analyst changes. The consensus target edged up to $177 from $174.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
